Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq: SIAL), today announced the expansion of its CompoZr Oncology Disease Model portfolio with the release of the first in its collection of breast cancer-specific knockout and knockin cell lines for drug discovery and research. These modified epithelial cell lines are expected to provide researchers with a characterized and known genetic background for basic research and pathway analysis. They are supplied with isogenic parental cell lines to allow high throughput, cell-based screening for drug discovery, target validation and mechanistic studies